Bicycle Therapeutics outlines 2026 milestones; zelenectide pevedotin dose selection & approval pathway update in Q1

BICYCLE THERAPEUTICS PLC

Dose selection from Phase 2/3 Duravelo-2 trial and approval update for zelenectide pevedotin in mUC expected in Q1 2026
Additional EphA2 human imaging data for radiopharmaceuticals pipeline planned for first half of 2026
Initial data from Phase 1/2 Duravelo-3 trial in NECTIN4-amplified breast cancer expected in second half of 2026
Financial runway expected into 2028 to support execution of clinical and strategic priorities

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.